Nancy J. Olsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nancy J. Olsen has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
B Kraft
Department of Medicine, Division of Rheumatology and Immunology, Vanderbilt University, Nashville TN 37232, USA
1 shared publicationB. Zhang
Department of Immunology and Division of Rheumatic Diseases
1 shared publicationC L Seehorn
Department of Medicine, Division of Rheumatology and Immunology, Vanderbilt University, Nashville TN 37232, USA
1 shared publicationC. Mohan
Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA
1 shared publicationD. R. Karp
Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA
1 shared publicationDennis K. Burns
Department of Pathology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas TX 75390
1 shared publication
Latest Publications
- 1 March 2010
- Published by Elsevier in Neuromuscular Disorders
- Vol. 20 (3) , 188-191
Autoantibody profiles in two patients with non-autoimmune muscle disease implicate a role for gliadin autoreactivity
- 1 March 2010
- Published by Elsevier in Neuromuscular Disorders
- Vol. 20 (3) , 188-191
Autoantibody profiles in two patients with non-autoimmune muscle disease implicate a role for gliadin autoreactivity
- Open Access
- 1 December 2009
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 159 (3) , 281-291
Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes
Interferon (IFN) signature genes have been shown to be expressed highly in peripheral blood of patients with systemic lupus erythematosus (SLE), especially in the presence of active disease. However, the expression of this gene signature in individuals with incomplete forms of lupus and the pathogenic relationship between IFN signature genes and autoantibody production have not been explored fully. In the present study, we examined the gene expression and autoantibody profiles of patients diagnosed with incomplete lupus erythematosus (ILE) to determine correlations of the gene expression signature with autoantibody production. Gene expression analysis was carried out on the 24K Illumina Human Refseq-8 arrays using blood samples from 84 subjects, including patients with SLE (n = 27) or ILE (n = 24), first-degree relatives (FDR) of these patients (n = 22) and non-autoimmune control (NC) individuals (n = 11). Autoantibody expression was measured using standard immunoassays and autoantigen proteomic arrays. Up-regulation of a set of 63 IFN signature genes was seen in 83% of SLE patients and 50% of ILE patients. High levels of IFN gene expression in ILE and SLE showed significant correlations with the expression of a subset of IgG autoantibodies, including chromatin, dsDNA, dsRNA, U1snRNP, Ro/SSA, La/SSB, topoisomerase I and Scl 70, while low IFN levels were correlated with immunoglobulin (Ig)M autoreactivity. These studies suggest that in patients with ILE the IFN gene expression signature may identify a subset of these individuals who are at risk for disease progression. Furthermore, high levels of alpha IFN may promote autoantibody class-switch from IgM to the more pathogenic IgG class.
- 1 December 2009
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 159 (3) , 281-291
Open AccessInterferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes
Interferon (IFN) signature genes have been shown to be expressed highly in peripheral blood of patients with systemic lupus erythematosus (SLE), especially in the presence of active disease. However, the expression of this gene signature in individuals with incomplete forms of lupus and the pathogenic relationship between IFN signature genes and autoantibody production have not been explored fully. In the present study, we examined the gene expression and autoantibody profiles of patients diagnosed with incomplete lupus erythematosus (ILE) to determine correlations of the gene expression signature with autoantibody production. Gene expression analysis was carried out on the 24K Illumina Human Refseq-8 arrays using blood samples from 84 subjects, including patients with SLE (n = 27) or ILE (n = 24), first-degree relatives (FDR) of these patients (n = 22) and non-autoimmune control (NC) individuals (n = 11). Autoantibody expression was measured using standard immunoassays and autoantigen proteomic arrays. Up-regulation of a set of 63 IFN signature genes was seen in 83% of SLE patients and 50% of ILE patients. High levels of IFN gene expression in ILE and SLE showed significant correlations with the expression of a subset of IgG autoantibodies, including chromatin, dsDNA, dsRNA, U1snRNP, Ro/SSA, La/SSB, topoisomerase I and Scl 70, while low IFN levels were correlated with immunoglobulin (Ig)M autoreactivity. These studies suggest that in patients with ILE the IFN gene expression signature may identify a subset of these individuals who are at risk for disease progression. Furthermore, high levels of alpha IFN may promote autoantibody class-switch from IgM to the more pathogenic IgG class.
- 17 December 2008
- Published by Springer Nature in Nature Clinical Practice Rheumatology
- Vol. 5 (2) , 68-69
Is there a role for everolimus in the treatment of RA?
The past decade has seen remarkable advances in the treatment of rheumatoid arthritis. Although this is good news for the majority of patients, one consequence is that the environment for the development of new drugs has become difficult as a result of high expectations for efficacy. Nevertheless, there remains a subgroup of patients with rheumatoid arthritis who are not candidates for treatment with the newer biologic agents and in whom oral DMARDs have certain advantages. A recent report by Bruyn et al. suggests that the proliferation-signal inhibitor everolimus could have unique properties, in addition to a convenient once-daily oral dosing schedule, that might fit this niche in the therapeutic armamentarium. Further studies are required, however, to confirm the disease-modifying effects and adverse event profile of this drug.
- 17 December 2008
- Published by Springer Nature in Nature Clinical Practice Rheumatology
- Vol. 5 (2) , 68-69
Is there a role for everolimus in the treatment of RA?
The past decade has seen remarkable advances in the treatment of rheumatoid arthritis. Although this is good news for the majority of patients, one consequence is that the environment for the development of new drugs has become difficult as a result of high expectations for efficacy. Nevertheless, there remains a subgroup of patients with rheumatoid arthritis who are not candidates for treatment with the newer biologic agents and in whom oral DMARDs have certain advantages. A recent report by Bruyn et al. suggests that the proliferation-signal inhibitor everolimus could have unique properties, in addition to a convenient once-daily oral dosing schedule, that might fit this niche in the therapeutic armamentarium. Further studies are required, however, to confirm the disease-modifying effects and adverse event profile of this drug.
- 12 June 2007
- Published by Springer Nature in Nature Clinical Practice Rheumatology
- Vol. 3 (8) , 430-431
Anti-TNF switching: effect on outcomes in patients with RA
- 12 June 2007
- Published by Springer Nature in Nature Clinical Practice Rheumatology
- Vol. 3 (8) , 430-431
Anti-TNF switching: effect on outcomes in patients with RA
- 1 September 2006
- Published by Springer Nature in Nature Clinical Practice Rheumatology
- Vol. 2 (9) , 472-473
Alternatives to methotrexate for infliximab combination therapy in rheumatoid arthritis
- 1 September 2006
- Published by Springer Nature in Nature Clinical Practice Rheumatology
- Vol. 2 (9) , 472-473
Alternatives to methotrexate for infliximab combination therapy in rheumatoid arthritis
- Open Access
- 6 April 2005
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 14 (10) , 1305-1314
Shared gene expression profiles in individuals with autoimmune disease and unaffected first-degree relatives of individuals with autoimmune disease
Patients with autoimmune disorders exhibit highly reproducible gene expression profiles in their peripheral blood mononuclear cells. These signatures may result from chronic inflammation, other disease manifestations, or may reflect family resemblance. To test the latter hypothesis, we determined gene expression profiles in unaffected first-degree relatives of individuals with autoimmune disease. Gene expression profiles in unaffected first-degree relatives resembled the profiles found in individuals with autoimmune diseases. A high percentage of differentially expressed genes in unaffected first-degree relatives were previously identified as autoimmune signature genes. Examination of the linear regression relationship of gene transcript levels between parent–offspring pairs revealed that autoimmune signature genes display high levels of family resemblance. Taken together, these results support the hypothesis that these variations in gene transcript levels are associated with family resemblance rather than clinical manifestations of disease.
- 6 April 2005
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 14 (10) , 1305-1314
Open AccessShared gene expression profiles in individuals with autoimmune disease and unaffected first-degree relatives of individuals with autoimmune disease
Patients with autoimmune disorders exhibit highly reproducible gene expression profiles in their peripheral blood mononuclear cells. These signatures may result from chronic inflammation, other disease manifestations, or may reflect family resemblance. To test the latter hypothesis, we determined gene expression profiles in unaffected first-degree relatives of individuals with autoimmune disease. Gene expression profiles in unaffected first-degree relatives resembled the profiles found in individuals with autoimmune diseases. A high percentage of differentially expressed genes in unaffected first-degree relatives were previously identified as autoimmune signature genes. Examination of the linear regression relationship of gene transcript levels between parent–offspring pairs revealed that autoimmune signature genes display high levels of family resemblance. Taken together, these results support the hypothesis that these variations in gene transcript levels are associated with family resemblance rather than clinical manifestations of disease.
- 1 April 2005
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 7 (2) , 106-114
Imaging and skeletal muscle disease
Imaging techniques have assumed increasing importance in the diagnostic approach to patients with muscle disease. These techniques include computed tomography, ultra-sound, and magnetic resonance imaging (MRI). For most disorders of muscle, ultrasound and MRI are more useful than computed tomography. Advantages of ultrasound include accessibility at the bedside and lower cost. However, MRI remains the gold standard for detecting changes in muscle tissue. In some cases, MRI examinations can take the place of muscle biopsy for diagnosis. New advances in MRI include diffusion-weighted imaging, which permits assessment of fluid motion in muscles, and blood-oxygen-level-dependent imaging to evaluate tissue oxygenation.
- 1 April 2005
- Published by Springer Nature in Current Rheumatology Reports
- Vol. 7 (2) , 106-114
Imaging and skeletal muscle disease
Imaging techniques have assumed increasing importance in the diagnostic approach to patients with muscle disease. These techniques include computed tomography, ultra-sound, and magnetic resonance imaging (MRI). For most disorders of muscle, ultrasound and MRI are more useful than computed tomography. Advantages of ultrasound include accessibility at the bedside and lower cost. However, MRI remains the gold standard for detecting changes in muscle tissue. In some cases, MRI examinations can take the place of muscle biopsy for diagnosis. New advances in MRI include diffusion-weighted imaging, which permits assessment of fluid motion in muscles, and blood-oxygen-level-dependent imaging to evaluate tissue oxygenation.
- Open Access
- 1 November 2004
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 63 (11) , 1387-1392
A gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells
Background: In previous studies the presence of a distinct gene expression pattern has been shown in peripheral blood cells from patients with autoimmune disease. Objective: To determine whether other specific signatures might be used to identify subsets of these autoimmune diseases and whether gene expression patterns in early disease might identify pathogenetic factors. Methods: Peripheral blood mononuclear cells were acquired from patients with rheumatoid arthritis (RA) and analysed by microarrays containing over 4300 named human genes. Patients with RA for Results: Cluster analyses permitted separation of the patients with early RA (ERA) from those with longstanding disease. Comparison with other patient groups suggested that the ERA signature showed some overlap with that seen in the normal immune response to viral antigen as well as with a subset of patients with systemic lupus erythematosus. Conclusions: The ERA signature may reflect, in part, a response to an unknown infectious agent. Furthermore, shared features with some lupus patients suggest that common aetiological factors and pathogenetic pathways may be involved in these two autoimmune disorders.
- 1 November 2004
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 63 (11) , 1387-1392
Open AccessA gene expression signature for recent onset rheumatoid arthritis in peripheral blood mononuclear cells
Background: In previous studies the presence of a distinct gene expression pattern has been shown in peripheral blood cells from patients with autoimmune disease. Objective: To determine whether other specific signatures might be used to identify subsets of these autoimmune diseases and whether gene expression patterns in early disease might identify pathogenetic factors. Methods: Peripheral blood mononuclear cells were acquired from patients with rheumatoid arthritis (RA) and analysed by microarrays containing over 4300 named human genes. Patients with RA for Results: Cluster analyses permitted separation of the patients with early RA (ERA) from those with longstanding disease. Comparison with other patient groups suggested that the ERA signature showed some overlap with that seen in the normal immune response to viral antigen as well as with a subset of patients with systemic lupus erythematosus. Conclusions: The ERA signature may reflect, in part, a response to an unknown infectious agent. Furthermore, shared features with some lupus patients suggest that common aetiological factors and pathogenetic pathways may be involved in these two autoimmune disorders.
- 1 October 2004
- Published by Elsevier in Best Practice & Research Clinical Rheumatology
- Vol. 18 (5) , 677-688
Drug-induced autoimmunity
- 1 October 2004
- Published by Elsevier in Best Practice & Research Clinical Rheumatology
- Vol. 18 (5) , 677-688
Drug-induced autoimmunity